文献速递胸部肿瘤

布格替尼治疗克唑替尼耐药间变性淋巴瘤激酶阳性非小细胞肺癌:一项随机多中心II期试验

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
PubMed 文献 · J Clin Oncol · 2017-05-05

该随机多中心II期试验纳入222例克唑替尼耐药ALK阳性NSCLC患者,比较布格替尼90mg每日一次(A组)与180mg每日一次(7天90mg导入,B组)。研究者评估确认客观缓解率A组45%、B组54%,中位无进展生存期A组9.2个月、B组12.9个月。B组疗效一致更优且安全性可接受。

要点

  • 布格替尼180mg(导入)较90mg在克唑替尼耐药ALK阳性NSCLC中显示一致更优的全身和颅内疗效。
  • 研究者评估确认客观缓解率A组45%、B组54%,中位无进展生存期A组9.2个月、B组12.9个月。
  • 常见治疗中出现的不良事件主要为1-2级,早期起病的肺部不良事件发生率为6%。

核心结论

  • 布格替尼产生显著的全身和颅内缓解以及稳健的无进展生存期;180mg(含导入)较90mg显示一致更优的疗效,且安全性可接受。

研究设计与样本

  • 随机、多中心、II期试验,患者按脑转移和克唑替尼最佳疗效分层,1:1随机分配至口服布格替尼90mg每日一次(A组)或180mg每日一次(7天90mg导入)(B组)。
  • 共入组222例患者(A组n=112,109例接受治疗;B组n=110,110例接受治疗),154例(69%)有基线脑转移,164/222例(74%)曾接受化疗。

主要发现

  • 中位随访8.0个月,研究者评估确认客观缓解率A组45%(97.5%CI,34%至56%),B组54%(97.5%CI,43%至65%)。
  • 研究者评估中位无进展生存期A组9.2个月(95%CI,7.4至15.6),B组12.9个月(95%CI,11.1至未达到)。
  • 独立评审委员会评估的基线可测量脑转移患者颅内客观缓解率A组42%(11/26例),B组67%(12/18例)。
  • 常见治疗中出现的不良事件为恶心(A组/B组,33%/40%)、腹泻(19%/38%)、头痛(28%/27%)、咳嗽(18%/34%),主要为1至2级。
  • 早期起病的肺部不良事件亚组发生于14/219例接受治疗患者(所有级别6%;≥3级3%),B组剂量递增至180mg后未再发生;14例中7例成功再挑战布格替尼。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods Patients were stratified by brain metastases and best response to crizotinib. They were randomly assigned (1:1) to oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]; arm B). Investigator-assessed confirmed objective response rate (ORR) was the primary end point. Results Of 222 patients enrolled (arm A: n = 112, 109 treated; arm B: n = 110, 110 treated), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. With 8.0-month median follow-up, investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A and 54% (97.5% CI, 43% to 65%) in arm B. Investigator-assessed median progression-free survival was 9.2 months (95% CI, 7.4 to 15.6) and 12.9 months (95% CI, 11.1 to not reached) in arms A and B, respectively. Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) in arm A and 67% (12 of 18 patients) in arm B. Common treatment-emergent adverse events were nausea (arm A/B, 33%/40%), diarrhea (arm A/B, 19%/38%), headache (arm A/B, 28%/27%), and cough (arm A/B, 18%/34%), and were mainly grades 1 to 2. A subset of pulmonary adverse events with early onset (median onset: day 2) occurred in 14 of 219 treated patients (all grades, 6%; grade ≥ 3, 3%); none occurred after escalation to 180 mg in arm B. Seven of 14 patients were successfully retreated with brigatinib. Conclusion Brigatinib yielded substantial whole-body and intracranial responses as well as robust progression-free survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017. PMID: 28475456. doi:10.1200/JCO.2016.71.5904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。